Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVXLNASDAQ:DAWNNASDAQ:NLTXNASDAQ:REPL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVXLAnavex Life Sciences$7.58+2.8%$8.61$3.51▼$14.44$647.12M0.821.22 million shs1.11 million shsDAWNDay One Biopharmaceuticals$6.31+0.2%$7.11$6.08▼$16.76$639.59M-1.241.11 million shs976,697 shsNLTXNeoleukin Therapeutics$17.09-1.1%$13.69$2.03▼$14.36$160.61M1.1150,104 shs167,843 shsREPLReplimune Group$8.43+0.1%$8.46$4.92▼$17.00$649.07M0.68925,556 shs1.09 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVXLAnavex Life Sciences+2.85%-2.57%-20.88%-3.44%+86.24%DAWNDay One Biopharmaceuticals+0.16%+0.32%-18.48%-33.16%-53.64%NLTXNeoleukin Therapeutics-1.10%-7.87%+10.90%-0.64%-46.11%REPLReplimune Group+0.12%-0.35%-9.06%-33.31%+62.74%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVXLAnavex Life Sciences3.7912 of 5 stars3.70.00.04.73.60.80.6DAWNDay One Biopharmaceuticals2.5974 of 5 stars4.60.00.00.03.02.50.0NLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AREPLReplimune Group4.0954 of 5 stars3.61.00.04.53.12.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVXLAnavex Life Sciences 3.33Buy$44.00480.47% UpsideDAWNDay One Biopharmaceuticals 3.13Buy$30.57384.49% UpsideNLTXNeoleukin Therapeutics 0.00N/AN/AN/AREPLReplimune Group 3.13Buy$19.43130.47% UpsideCurrent Analyst Ratings BreakdownLatest NLTX, REPL, AVXL, and DAWN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2025DAWNDay One BiopharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$25.005/7/2025DAWNDay One BiopharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $27.004/7/2025AVXLAnavex Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.00 ➝ $42.004/7/2025AVXLAnavex Life SciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$46.00 ➝ $46.004/3/2025DAWNDay One BiopharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00 ➝ $36.003/31/2025AVXLAnavex Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.00 ➝ $42.003/25/2025DAWNDay One BiopharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$39.00 ➝ $27.003/5/2025DAWNDay One BiopharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$39.00 ➝ $34.00(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVXLAnavex Life SciencesN/AN/AN/AN/A$1.42 per shareN/ADAWNDay One Biopharmaceuticals$161.92M3.95N/AN/A$3.98 per share1.59NLTXNeoleukin TherapeuticsN/AN/AN/AN/A$11.08 per shareN/AREPLReplimune GroupN/AN/AN/AN/A$6.26 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVXLAnavex Life Sciences-$43M-$0.55N/AN/AN/AN/A-37.50%-34.08%8/5/2025 (Estimated)DAWNDay One Biopharmaceuticals-$188.92M-$0.71N/AN/AN/AN/A-22.40%-19.79%7/8/2025 (Estimated)NLTXNeoleukin Therapeutics-$57.56M-$3.11N/A∞N/AN/A-37.22%-30.91%N/AREPLReplimune Group-$215.79M-$3.07N/AN/AN/AN/A-54.84%-42.97%8/6/2025 (Estimated)Latest NLTX, REPL, AVXL, and DAWN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/22/2025Q4 2025REPLReplimune Group-$0.75-$0.82-$0.07-$0.82N/AN/A5/13/2025Q2 2025AVXLAnavex Life Sciences-$0.16-$0.13+$0.03-$0.13N/AN/A5/6/2025Q1 2025DAWNDay One Biopharmaceuticals-$0.46-$0.35+$0.11-$0.35$30.28 million$30.76 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVXLAnavex Life SciencesN/AN/AN/AN/AN/ADAWNDay One BiopharmaceuticalsN/AN/AN/AN/AN/ANLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/AREPLReplimune GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVXLAnavex Life SciencesN/A9.459.45DAWNDay One BiopharmaceuticalsN/A14.6214.55NLTXNeoleukin TherapeuticsN/A15.3315.33REPLReplimune Group0.1411.4311.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVXLAnavex Life Sciences31.55%DAWNDay One Biopharmaceuticals87.95%NLTXNeoleukin Therapeutics52.37%REPLReplimune Group92.53%Insider OwnershipCompanyInsider OwnershipAVXLAnavex Life Sciences11.00%DAWNDay One Biopharmaceuticals6.20%NLTXNeoleukin Therapeutics1.58%REPLReplimune Group8.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVXLAnavex Life Sciences4085.37 million75.71 millionOptionableDAWNDay One Biopharmaceuticals60101.36 million92.38 millionOptionableNLTXNeoleukin Therapeutics909.40 million9.25 millionNo DataREPLReplimune Group21077.09 million70.24 millionOptionableNLTX, REPL, AVXL, and DAWN HeadlinesRecent News About These CompaniesHC Wainwright Estimates Replimune Group Q3 EarningsMay 27 at 2:07 AM | marketbeat.comAnalysts Offer Predictions for Replimune Group Q1 EarningsMay 27 at 1:57 AM | americanbankingnews.comLeerink Partnrs Estimates Replimune Group Q1 EarningsMay 27 at 1:51 AM | marketbeat.comReplimune’s SWOT analysis: biotech firm’s stock poised for growth amid FDA reviewMay 26 at 9:59 PM | investing.comReplimune Group, Inc. (NASDAQ:REPL) Shares Acquired by Woodline Partners LPMay 25, 2025 | marketbeat.comMillennium Management LLC Acquires 34,841 Shares of Replimune Group, Inc. (NASDAQ:REPL)May 25, 2025 | marketbeat.comReplimune Group (NASDAQ:REPL) Shares Gap Up - Here's WhyMay 24, 2025 | marketbeat.comTraders Buy High Volume of Replimune Group Call Options (NASDAQ:REPL)May 24, 2025 | marketbeat.comEarnings call transcript: Replimune Q1 2025 sees stock drop post-earningsMay 24, 2025 | uk.investing.comREPLIMUNE GROUP Earnings Results: $REPL Reports Quarterly EarningsMay 24, 2025 | nasdaq.comReplimune Group Sees Unusually Large Options Volume (NASDAQ:REPL)May 24, 2025 | americanbankingnews.comReplimune Group, Inc. (NASDAQ:REPL) Q4 2025 Earnings Call TranscriptMay 23, 2025 | insidermonkey.comEmily Luisa Hill Sells 2,535 Shares of Replimune Group, Inc. (NASDAQ:REPL) StockMay 23, 2025 | insidertrades.comPoint72 Asset Management L.P. Buys Shares of 283,966 Replimune Group, Inc. (NASDAQ:REPL)May 23, 2025 | marketbeat.comQ4 2025 Replimune Group Inc Earnings CallMay 23, 2025 | uk.finance.yahoo.comReplimune Group, Inc. (REPL) Q4 2025 Earnings Call TranscriptMay 22, 2025 | seekingalpha.comReplimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides Corporate UpdateMay 22, 2025 | globenewswire.comNorthern Trust Corp Acquires 40,134 Shares of Replimune Group, Inc. (NASDAQ:REPL)May 22, 2025 | marketbeat.comVelan Capital Investment Management LP Acquires Shares of 181,367 Replimune Group, Inc. (NASDAQ:REPL)May 21, 2025 | marketbeat.comSoleus Capital Management L.P. Acquires Shares of 262,500 Replimune Group, Inc. (NASDAQ:REPL)May 21, 2025 | marketbeat.comReplimune Group, Inc. (NASDAQ:REPL) Stock Holdings Lifted by Tang Capital Management LLCMay 20, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNLTX, REPL, AVXL, and DAWN Company DescriptionsAnavex Life Sciences NASDAQ:AVXL$7.58 +0.21 (+2.85%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$7.74 +0.16 (+2.11%) As of 05:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.Day One Biopharmaceuticals NASDAQ:DAWN$6.31 +0.01 (+0.16%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$6.39 +0.08 (+1.27%) As of 04:54 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.Neoleukin Therapeutics NASDAQ:NLTX$17.09 -0.19 (-1.10%) As of 05/27/2025Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.Replimune Group NASDAQ:REPL$8.43 +0.01 (+0.12%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$8.75 +0.32 (+3.80%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Amer Sports: The New ONON and DECK of Consumer Discretionary? BigBear.ai: Risky AI Stock or Defense Tech Opportunity? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
